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ABSTRACT
Background: Moderate vitamin B-12 deficiency is relatively com-
mon in older people. However, there is little robust evidence on the
effect of vitamin B-12 supplementation on neurologic and cognitive
outcomes in later life.
Objective: We investigated whether vitamin B-12 supplementation
benefits neurologic and cognitive function in moderately vitamin
B-12–deficient older people.
Design: We conducted a double-blind, randomized, placebo-controlled
trial in 7 general practices in South East England, United Kingdom.
Study participants were aged $75 y and had moderate vitamin B-12
deficiency (serum vitamin B-12 concentrations: 107–210 pmol/L) in the
absence of anemia and received 1 mg crystalline vitamin B-12 or
a matching placebo as a daily oral tablet for 12 mo. Peripheral motor
and sensory nerve conduction, central motor conduction, a clinical neu-
rologic examination, and cognitive function were assessed before and
after treatment.
Results: A total of 201 participants were enrolled in the trial, and
191 subjects provided outcome data. Compared with baseline,
allocation to vitamin B-12 was associated with a 177% increase
in serum concentration of vitamin B-12 (641 compared with
231 pmol/L), a 331% increase in serum holotranscobalamin (240
compared with 56 pmol/L), and 17% lower serum homocysteine (14.2
compared with 17.1 mmol/L). In intention-to-treat analysis of co-
variance models, with adjustment for baseline neurologic function,
there was no evidence of an effect of supplementation on the pri-
mary outcome of the posterior tibial compound muscle action po-
tential amplitude at 12 mo (mean difference: 20.2 mV; 95% CI:
–0.8, 0.3 mV). There was also no evidence of an effect on any
secondary peripheral nerve or central motor function outcome, or
on cognitive function or clinical examination.
Conclusion: Results of the trial do not support the hypothesis
that the correction of moderate vitamin B-12 deficiency, in the
absence of anemia and of neurologic and cognitive signs or
symptoms, has beneficial effects on neurologic or cognitive func-
tion in later life. This trial was registered at www.isrctn.com as
ISRCTN54195799. Am J Clin Nutr 2015;102:639–47.
Keywords: cognitive, neurologic, older people, vitamin B-12,
peripheral and central nerve conduction
INTRODUCTION
Vitamin B-12 deficiency, which is frequently attributable to
age-related gastric atrophy, is relatively common in later life and
affects about one-sixth of people aged .75 y in the United
Kingdom (1). Vitamin B-12 is required for the methylation of
myelin, neurotransmitters, and membrane phospholipids and is
essential for the integrity of the central and peripheral nervous
systems (2, 3). Severe deficiency of vitamin B-12 typically
presents as sensory disturbances in the extremities (tingling and
numbness) and loss of vibration and joint position sense, together
with motor problems and abnormalities of gait, impaired cognition,
and depression (2, 3). Neurologic and cognitive manifestations of
severe vitamin B-12 deficiency are largely responsive to treatment
with vitamin B-12 (repeated intramuscular injection), although
improvement may take time (4), and the severity and duration of
neurologic abnormalities influence the degree of recovery (2, 3).
Neurologic, cognitive, and psychological abnormalities also occur
in individuals withmoderate vitamin B-12 deficiency (serum vitamin
B-12 concentrations: 107–210 pmol/L) (5), although the evidence of
a direct association between vitamin B-12 status and neurologic
function (6–9) or cognitive function (10, 11) has been mixed. Oral
supplementation with crystalline vitamin B-12 is routinely used to
correct hematologic variables of moderate deficiency (2, 3, 12), but
to our knowledge, there has been no previous evidence on the ef-
ficacy of treatment of neurologic or cognitive function in older
people with moderate vitamin B-12 deficiency (2, 3).
1 Supportedby the Food Standards Agency (N05072) and the Department of
Health. National Health Service Research and Development and King’s College
Hospital Trust Research and Development provided service support costs. DSM
donated the vitamin B-12 form used to manufacture study tablets. This is an open
access article distributed under the CC-BY license (http://creativecommons.org/
licenses/by/3.0/).
2 The funders had no role in the implementation, data collection, manage-
ment, analysis, or interpretation of the study or in the preparation, review,
and approval of the manuscript.
*Towhom correspondence should be addressed. E-mail: alan.dangour@
lshtm.ac.uk.
ReceivedMarch 10, 2015. Accepted for publication June 5, 2015.
First published online July 1, 2015; doi: 10.3945/ajcn.115.110775.
Am J Clin Nutr 2015;102:639–47. Printed in USA. 639
The aim of the current trial was to determine whether daily
supplementation for 12 mo with 1 mg vitamin B-12 or a placebo
in older people with moderate vitamin B-12 deficiency in the
absence of anemia would have beneficial effects on peripheral
and central neurologic function and on cognitive function.
METHODS
Participants
Details of the trial protocol have been published (www.isrctn.
com; ISRCTN54195799) (13). Participants aged $75 y were
enrolled at 7 general practices in South East England that were
members of the Medical Research Council General Practice
Research Framework or the National Institute of Health Re-
search Primary Care Research Network. Potentially eligible
participants were identified by a computer search after the ex-
clusion of individuals with diabetes, dementia, or epilepsy. An
additional manual check of health records was carried out by
trained nurses to exclude individuals with alcohol addiction,
pacemakers, or other implanted metallic devices (for whom
central neurophysiologic testing was contraindicated), residents
of nursing homes, and anyone with a previous diagnosis of
pernicious anemia. After confirmation by their general practi-
tioners, eligible individuals were invited by mail to participate in
the trial. Individuals who reported current consumption of vi-
tamin B-12 supplements or who had received a vitamin B-12
injection in the previous 6 mo were excluded. Interested eligible
participants were invited to attend their general practices for
a screening appointment where research nurses clarified any
queries and administered the Mini-Mental State Examination
(14) to exclude significant cognitive impairment. Participants
with a Mini-Mental State Examination score $24 (maximum
score: 30) were asked to provide a blood sample to assess serum
vitamin B-12 and hemoglobin concentrations. Individuals with
very-low vitamin B-12 concentrations (,107 pmol/L, which is
a cutoff typically used for deficiency; Beckman Coulter assay,
Beckman Coulter Inc.) or who were shown to have anemia
(hemoglobin concentration ,110 g/L for women and ,120 g/L
for men) were excluded and referred to their general practi-
tioners for additional assessment. Individuals with moderate
vitamin B-12 deficiency who did not have anemia (serum vita-
min B-12 concentrations $107 and ,210 pmol/L [Beckman
Coulter assay (1)] and hemoglobin concentrations $110 g/L for
women and$120 g/L for men) were eligible to join the trial and
were invited to attend a baseline appointment at King’s College
Hospital, London.
Procedures
At the baseline appointment, the study manager discussed the
trial with potential participants and obtained written informed
consent before random treatment allocation. Allocation codes were
obtained from a central computerized randomization service.
Allocation to treatment was balanced by age (75–79 and $80 y)
and sex. Allocated treatment consisted of a single tablet admin-
istered daily that was identical in size, shape, color, smell, and
taste for both the intervention and placebo and packaged into
identical pots each of which contained 70 tablets. Each in-
tervention tablet contained 1 mg vitamin B-12 (cyanocobalamin).
The dose was selected to be greater than the minimum Recom-
mended Daily Intake (2.5 mg) required to correct vitamin B-12
deficiency in older people (15) and is safe (16) (there is no defined
dietary intake upper limit for vitamin B-12). Becausew1–2% of
an oral dose of vitamin B-12 is absorbed (by passive diffusion),
this dose would be expected to provide 10–20 mg/d in the
absence of an intrinsic factor required for active absorp-
tion (12). All study personnel were blinded to the treatment
allocation.
Before the baseline appointment, participants were invited to
complete a postal questionnaire that was used to collect in-
formation on diet and alcohol consumption. Psychological
health was also assessed by postal questionnaire at baseline and
12 mo with the 30-item General Health Questionnaire (17). At
the baseline appointment, data were collected on educational
history and history of previous stroke or myocardial infarction.
Data were also collected on current prescribed medication. At
baseline and 12 mo after random assignment, height (to the
nearest 0.1 cm) and weight (to the nearest 0.1 kg) were mea-
sured, and the timed up-and-go test (18) was administered to
assess mobility.
Assessment of neurologic function
At baseline and after 12 mo, a single physician (KM) assessed
clinical measures of neurologic function (presence or absence of
knee and ankle jerks and of joint position sense and vibration
sense in the great toe) and conducted a standard battery of pe-
ripheral nerve-conduction tests (including motor and sensory
nerve conduction in the right superficial peroneal, sural, common
peroneal, and tibial nerves), and central motor conduction tests.
Skin temperature of the dorsum of the foot was measured, which
allowed for correction for temperature differences between first
and second visits. The sensory action potential (SAP)8 amplitude
(maximum deviation of the electrical response) and conduction
velocity (distance divided by onset latency) were measured.
Common peroneal, tibial, and ulnar motor conduction were
measured by recording from extensor digitorum brevis, abductor
hallucis (AH), and abductor digiti minimi (ADM) muscles, re-
spectively. Nerves were stimulated supramaximally at proximal
and distal sites, and conduction velocity was calculated. Com-
pound muscle action potential (CMAP) amplitude, distal motor
latency, and F-wave latency (a measure of conduction time from
the distal stimulation site to the spinal cord) were also measured.
Central motor conduction in the corticospinal tract was
measured by using transcranial magnetic stimulation, which
painlessly and noninvasively excites the motor cortex (19). A
13-cm diameter circular coil connected to a magnetic stimulator
that provided a monophasic pulse was centered over the vertex to
excite the hand area of the left motor cortex. The threshold for
excitation was determined by using a standard technique (20).
With the right ADM muscle partially activated voluntarily,
8 stimuli at 1.2 times the threshold were delivered to evoke mo-
tor evoked potentials (MEPs), the mean amplitude and mini-
mal latency of which were measured. The time to response
8Abbreviations used: ADM, abductor digiti minimi; AH, abductor hallu-
cis; CMAP, compound muscle action potential; CVLT, California Verbal
Learning Test; MEP, motor evoked potential; SAP, sensory action potential.
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in a given muscle was subtracted from an estimate of the
peripheral nerve conduction time to calculate the central motor
conduction time. Similarly, by using a double cone coil, the leg
area of motor cortex was excited to measure MEPs evoked in
AHs. Each participant received a maximum of 70 brain stimuli.
Any individuals shown to have significant neurologic deficit
were referred to their general practitioners for additional
assessment.
The primary outcome of the trial was the posterior tibial
CMAP amplitude evoked by distal stimulation. The negative
peak amplitude of the peripherally evoked CMAP reflects the
number of motor axons that can be accessed by an electrical
stimulus, which, in turn, reflects muscle strength (21, 22). Of
10 secondary neurologic outcomes, 3 outcomes assessed
motor nerve conduction (posterior tibial conduction velocity,
common peroneal CMAP amplitude, and common peroneal
conduction velocity), 4 outcomes assessed sensory nerve con-
duction (sural SAP amplitude, sural conduction velocity, su-
perficial peroneal SAP amplitude, and superficial peroneal
conduction velocity), and 3 outcomes assessed central nerve con-
duction (mean right ADMMEP amplitude, central motor conduction
time to the right ADM, and central motor conduction time to the
right AH).
Assessment of cognitive function
At baseline and after 12 mo, the study manager (KW) ad-
ministered a range of cognitive function tests. In accordance with
international guidance (23), the main cognitive outcome was
a test of memory, i.e., a 16-item word list from the California
Verbal Learning Test (CVLT) (24). The sum of words recalled
after each of 3 repeats and the number of words recalled after
a 20-min delay formed the main cognitive outcome. The identical
version of the CVLTwas used at baseline and after 12 mo. Other
cognitive outcomes were as follows: processing speed assessed
by using the oral version of the symbol letter modality test
(25) for which the outcome was the number correct in 90 s;
simple and choice reaction time (26) assessed by using an
electronic reaction timer that provided 20 single (simple reaction
time) or 40 multiple (choice reaction time) challenges; and
FIGURE 1 Consolidated Standards of Reporting Trial flowchart for the Older People and Enhanced Neurological Function study. MMSE, Mini-Mental
State Examination.
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executive-function assessed by using a verbal fluency test (animal
naming) over 60 s (27).
Adherence to randomized intervention
Adherence to allocated treatment was measured by counting
the number of tablets returned at the end of the study. At baseline
and 12 mo after random assignment, blood samples were
collected to measure serum concentrations of vitamin B-12 (mi-
crobiologic assay; CV range: 5–7%), holotranscobalamin (Axis-
Shield radioimmunoassay; CV range: 5–8%; Axis-Shield plc),
total homocysteine (Abbott IMx analyzer; CV range: 2–3%;
Abbott Laboratories), and folate (chloramphenicol-resistant
microbiologic assay; CV range: 5–8%). A full blood count was
analyzed for hemoglobin. Baseline appointments were held, on
average, a median of 63 d (IQR: 38–119 d) after the screening
appointment. At baseline, vitamin B-12 was assessed by using
a microbiologic assay (that estimated serum concentrations
w25% higher than did the Beckman Coulter method used at the
screening appointment), and confirmed that randomly assigned
participants had low vitamin B-12 status at study entry (88% of
subjects had vitamin B-12 status below the median value for the
microbiologic assay) and did not have anemia. There were no
preset criteria for participant withdrawal during the trial. Any
participants who stopped taking the study medication were in-
vited to attend their scheduled follow-up assessment at 12 mo.
Statistical analysis
A sample size of 100 individuals for each allocated treatment
group was selected that, with an assumed 30% dropout over
12 mo, would have given 90% power to detect a$28% change in
the primary outcome of posterior tibial CMAP amplitude with
5% significance. Posterior tibial CMAP amplitude is a marker of
TABLE 1
Baseline characteristics of OPEN study participants by allocated treatment1
Vitamin B-12 Placebo
Participants, n 99 102
Sex, M, n (%) 46 (46.5) 48 (47.1)
Age
Age, y 79.9 6 3.52 80.1 6 3.7
75–79, n (%) 56 (56.6) 57 (55.9)
$80, n (%) 43 (43.4) 45 (44.1)
Education
Age at leaving, y 18.3 6 5.3 17.8 6 6.6
No qualifications, n (%) 21 (21.4) 33 (33.0)
Basic or clerical, n (%) 16 (16.3) 18 (18.0)
Advanced or university, n (%) 33 (33.7) 19 (19.0)
Other, n (%) 28 (28.6) 30 (30.0)
Vascular health
Myocardial infarction in 5 y, n (%) 1 (1.0) 4 (3.9)
Stroke in 5 y, n (%) 1 (1.0) 0
BMI, kg/m2 27.0 6 5.6 27.5 6 5.3
,18.5, n (%) 1 (1.0) 0
$30, n (%) 18 (18.2) 25 (24.8)
Mini-Mental State Examination score 29 (28–29)3 29 (28–29)
Current prescription drugs,4 n (%)
Statins 32 (38.1) 35 (44.9)
Proton-pump inhibitors 26 (31.0) 27 (34.6)
Other relevant 1 (1.2) 2 (2.6)
Dietary pattern, n (%)
.1 portion meat/wk 69 (73.4) 70 (72.2)
.1 portion oily fish/wk 16 (18.0) 22 (23.4)
.1 portion white fish/wk 21 (21.9) 18 (18.8)
.1 portion eggs/wk 47 (48.5) 38 (39.2)
Daily alcohol 33 (34.4) 35 (35.4)
Blood biochemical measure
Participants, n 86 84
Vitamin B-12, pmol/L 222.9 (197.4–268.9) 228.0 (194.7–271.0)
Holotranscobalamin, pmol/L 50.4 (38.2–68.3) 48.8 (39.8–62.9)
Homocysteine, mmol/L 15.9 (14.0–18.9) 16.3 (13.3–19.9)
Folate, nmol/L 17.7 (10.8–25.4) 17.5 (11.8–25.4)
Hemoglobin, g/L 139.8 6 11.1 138.9 6 12.9
1OPEN, Older People and Enhanced Neurological Function.
2Mean 6 SD (all such values).
3Median; IQR in parentheses (all such values).
4Drug categories were as follows: statins (simvastatin, atorvastatin, pravastatin, and rosuvastatin); proton-pump in-
hibitors (omeprazole, lansoprazole, esomeprazole, rabeprazole, and pantoprazole); and other relevant drugs (amiodarone
and metronidazole).
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foot muscle strength, and a 28% increase is likely to be asso-
ciated with clinically relevant improvements in physical co-
ordination and balance in older people (28, 29). The primary
analysis was carried out on an intention-to-treat basis. The
ANCOVA models were adjusted for baseline measures. Ad-
justed models further allowed for age and sex, and in the case of
the primary outcome, we also adjusted for skin temperature. All
models with continuous outcomes were boot strapped to allow
for nonnormal distributions. ORs for binary variables were
calculated by using logistic regression. Variables that were not
normally distributed are presented as medians with IQRs. No
subgroup analysis was prespecified. An independent data mon-
itoring and safety committee assessed safety data. Results are
presented as appropriate effect sizes with 95% CIs. This study
was reviewed and approved by the National Research Ethics
Committee (08/H0305/18) and the London School of Hygiene &
Tropical Medicine Ethics Committee (no. 5298).
RESULTS
Study participants
Participants were screened between November 2008 and
February 2010. Invitation letters were sent to 3071 potential
participants, and 487 individuals (16%) agreed to attend a
screening appointment (Figure 1). After screening, 262 po-
tential participants were shown to be ineligible, largely because
their serum vitamin B-12 concentrations were out of range. Of
209 participants who were randomly allocated to the study be-
tween January 2009 and May 2010, 8 subjects were randomly
assigned in error (as a result of protocol deviations) and pro-
vided no additional data. Valid data at baseline were available on
201 participants. Six participants withdrew from the study
(2 subjects from the vitamin B-12 arm and 4 subjects from the
placebo arm), and one participant died. There were no other
reported serious adverse events. Three individuals who contin-
ued study medication (all allocated to vitamin B-12) did not
provide any data at 12 mo. Outcome data on 191 participants
(95% of randomly assigned subjects) were available after 12 mo
of intervention. At baseline, sociodemographic variables, med-
ical history, use of prescribed medication, diet, and serum
B-vitamin status were similar between allocated groups (Table 1).
The study arms were well matched at baseline for neurologic
(Table 2), cognitive, and psychological (Table 3) function
outcomes.
Intervention participation
Participants were provided with 420 tablets over the course of
the study and continued to receive the randomized treatment for
an average of 389 d. There was no difference between trial arms
in the number of tablets returned at the end of the study (mean: 37
tablets in the vitamin B-12 arm and 39 tablets in the placebo arm).
The number of tablets apparently consumed closely matched the
number of days in the study, which confirmed a very high level of
TABLE 2
Neurologic function at baseline by allocated treatment1
Vitamin B-12 (n = 99) Placebo (n = 100)2
Motor nerve conduction
Posterior tibial CMAP amplitude (primary outcome), mV 4.6 (0–18.0)3 4.9 (0–13.6)
Posterior tibial conduction velocity,4 m/s 39.9 6 5.05 40.1 6 5.2
Common peroneal CMAP amplitude, mV 2.2 (0–8.8) 2.5 (0–8.2)
Common peroneal conduction velocity,4 m/s 42.5 6 4.6 43.0 6 4.1
Sensory nerve conduction
Sural SAP amplitude, mV 3.8 (0–17.5) 3.8 (0–14.2)
Sural conduction velocity,6 m/s 40.6 6 5.2 40.2 6 5.3
Superficial peroneal SAP amplitude, mV 2.4 (0–13.2) 3.4 (0–16.7)
Superficial peroneal conduction velocity,7 m/s 41.2 6 6.0 41.0 6 5.2
Central motor conduction
Right abductor digiti minimi motor evoked potential
amplitude, mV
3.3 6 1.4 3.4 6 1.5
Central motor conduction time, right abductor
digiti minimi, ms
5.5 6 1.2 5.5 6 1.4
Central motor conduction time, right abductor
hallucis,4 ms
13.6 6 3.3 13.6 6 3.5
Clinical nerve outcomes
Absent right leg knee jerk, n (%) 11 (11.1) 8 (8.0)
Absent right leg ankle jerk, n (%) 33 (33.3) 22 (22.0)
Absent right great toe position sense, n (%) 4 (4.0) 8 (8.0)
Absent right great toe vibration sense, n (%) 66 (66.7) 66 (66.0)
Timed up-and-go, s 10.4 6 3.0 10.7 6 3.5
1CMAP, compound muscle action potential; SAP, sensory action potential.
2Two participants randomly assigned to placebo provided no baseline nerve function data.
3Median; range in parentheses (all such values).
4Small amounts of missing data (n , 10 in each arm).
5Mean 6 SD (all such values).
6Missing data (n = 11 in vitamin B-12 and n = 16 in placebo).
7Missing data (n = 23 in vitamin B-12 and n = 17 in placebo).
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adherence with allocated treatment (.97%). Blood samples were
available from 151 participants at both baseline and 12 mo
(Table 4). Allocation to vitamin B-12 was associated with a
177% increase compared with baseline in serum vitamin B-12 (641
compared with 231 pmol/L), a 331% increase compared with base-
line in serum holotranscobalamin (240 compared with 56 pmol/L),
and 17% lower serum homocysteine compared with baseline
(14.2 compared with 17.1 mmol/L). In comparison, compared
with baseline amounts, allocation to the placebo was associated
with small changes (0–5%) in biochemical variables (Table 4).
Effects on neurologic function
Of participants allocated to the placebo arm, the nerve con-
duction test-retest correlation for the primary outcome of pos-
terior tibial CMAP amplitude was 0.82, which showed a high
level of reliability of nerve conduction measurements. Change in
the primary outcome over the course of the study was small in
both vitamin B-12 and placebo arms. There was no evidence of
effect on the primary outcome by allocated treatment at 12 mo
(mean difference: 20.2 mV; 95% CI: –0.8, 0.3 mV) or on any
secondary peripheral nerve or central motor function outcome
or on clinical examination (Table 5). Additional adjustment for
age and sex did not alter these findings (Table 5).
Effects on cognitive function and other secondary outcomes
The change in the main cognitive function outcome of the
CVLT over the course of the study was small in both the vitamin
B-12 and placebo arms. There was no evidence of an effect by
allocated treatment on the CVLT at 12 mo (mean difference:
21.4 words; 95% CI:22.9, 0.1 words) or on any other cognitive
function outcome or psychological health (Table 6).
DISCUSSION
We randomly assigned 201 nonanemic adults aged$75 y who
had moderate vitamin B-12 deficiency to receive 1 mg vitamin
B-12 or placebo/d for 12 mo. At baseline, participant charac-
teristics, the primary outcome, and secondary neurologic and
cognitive outcomes were well matched by allocated treatment
groups, and loss to follow-up over 12 mo was ,5%. The sub-
stantial changes in blood concentrations of vitamin B-12, holo-
transcobalamin, and homocysteine, in response to the allocated
treatments showed a high level of adherence to the allocated
study treatment over 12 mo. However, results of this trial
showed no evidence of an effect on any measure of peripheral or
central nerve conduction or of cognitive function by allocated
treatment and did not provide any evidence that correction of
moderate vitamin B-12 deficiency in the absence of anemia has
beneficial effects on neurologic or cognitive function.
We identified trial participants with moderate vitamin B-12
status by using standard clinical testing procedures (serum vi-
tamin B-12 concentration) (3). This identification was done to
enhance the relevance of our trial for population health in older
people although the appropriateness of various hematologic tests
to assess vitamin B-12 status is currently under review (30). We
selected neurologic and cognitive assessments for our trial that
TABLE 3
Cognitive and psychological function at baseline by allocated treatment1
Vitamin B-12 (n = 99) Placebo (n = 102)
California Verbal Learning Test
Total words correct in first 3 trials, n 22.8 6 6.0 22.0 6 6.5
Words recalled at delayed recall, n 7.3 6 2.6 7.0 6 3.1
Symbol letter modality,2 n correct 41.1 6 9.5 39.6 6 12.5
Reaction time, s
Simple 0.3 6 0.1 0.3 6 0.1
Choice 0.7 6 0.1 0.7 6 0.2
Verbal fluency, n animals named 21.4 6 5.4 21.3 6 6.0
30-item General Health Questionnaire score3 2.5 6 4.7 2.9 6 4.7
1All values are means 6 SDs.
2Missing data (n = 1 in vitamin B-12 and n = 1 in placebo).
3Missing data (n = 8 in vitamin B-12 and n = 9 in placebo).
TABLE 4
Effects of vitamin B-12 on serum concentrations of vitamin B-12, holotranscobalamin, homocysteine, folate, and hemoglobin1
Serum measure
Vitamin B-12 Placebo
n Baseline 12 mo
Change from
baseline, % n Baseline 12 mo
Change from
baseline, %
Vitamin B-12, pmol/L 74 231.3 6 52.02 640.9 6 199.3 177 70 235.4 6 60.7 235.7 6 77.5 0
Holotranscobalamin, pmol/L 71 55.7 6 21.5 240.0 6 162.9 331 70 51.8 6 17.5 54.2 6 29.5 5
Homocysteine, mmol/L 73 17.1 6 4.6 14.2 6 4.2 217 70 17.2 6 5.6 17.4 6 6.0 1
Folate, nmol/L 72 20.7 6 12.3 20.2 6 11.6 22 71 21.0 6 13.8 20.4 6 14.0 23
Hemoglobin, g/L 78 140.5 6 11.0 140.0 6 10.7 0 71 137.9 6 12.8 137.2 6 12.6 0
1Small amounts of missing data (n , 10/analyte).
2Mean 6 SD (all such values).
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relate to strength, coordination, mobility, memory, processing
speed, and executive function and are highly relevant to pop-
ulation health and quality of life in older people. Nerve con-
duction tests, in particular, provided objective measures of
neurologic function by using state-of-the-art methods, and all
testing was conducted by a single expert clinician both at baseline
and study endpoint, which eliminated interobserver variability.
We collected clinical measures of neurologic function (e.g., knee
and ankle jerks and others) to support the relevance of the study.
The study protocol was designed to minimize inconvenience
TABLE 5
Effects of vitamin B-12 on the primary and secondary neurologic function outcomes at 12 mo1
Vitamin B-12 (n = 91) Placebo (n = 91)
Unadjusted effect
size2,3
Adjusted effect
size3,4
Motor nerve conduction
Posterior tibial CMAP amplitude (primary outcome), mV 4.7 (0–15.3)5 5.3 (0–17.1) 20.2 (20.8, 0.3) 20.2 (20.9, 0.3)
Posterior tibial conduction velocity, m/s 39.1 6 0.56 40.2 6 0.5 20.7 (22.0, 0.5) 20.9 (22.1, 0.6)
Common peroneal CMAP amplitude, mV 2.3 (0–8.0) 2.3 (0–6.6) 0.0 (20.3, 0.3) 20.0 (20.3, 0.3)
Common peroneal conduction velocity, m/s 42.3 6 0.5 43.1 6 0.5 20.4 (21.3, 0.7) 20.4 (21.6, 0.6)
Sensory nerve conduction
Sural SAP amplitude, mV 3.2 (0–18.7) 3.1 (0–18.5) 20.6 (21.5, 0.2) 20.5 (21.4, 0.3)
Sural conduction velocity,7 m/s 40.3 6 0.5 40.9 6 0.5 21.0 (22.2, 0.3) 21.1 (22.5, 0.1)
Superficial peroneal SAP amplitude, mV 3.1 (0–19.5) 3.2 (0–14.5) 0.1 (20.7, 1.0) 0.1 (20.7, 1.1)
Superficial peroneal conduction velocity,8 m/s 40.8 6 0.6 40.8 6 0.5 20.6 (22.3, 1.4) 20.4 (22.1, 1.2)
Central motor conduction
Right abductor digiti minimi motor evoked potential
amplitude, mV
3.5 6 0.1 3.6 6 0.1 0.0 (20.3, 0.4) 0.0 (20.3, 0.4)
Central motor conduction time, right abductor
digiti minimi, ms
6.2 6 0.1 6.2 6 0.1 20.0 (20.4, 0.4) 20.0 (20.4, 0.4)
Central motor conduction time, right abductor
hallucis,9 ms
14.0 6 0.3 14.0 6 0.3 0.1 (20.8, 1.1) 0.1 (20.8, 1.1)
Clinical nerve outcomes
Absent right leg knee jerk, n (%) 14 (15.4) 9 (9.9) 1.2 (0.4, 3.7)10 1.1 (0.3, 3.6)10
Absent right leg ankle jerk, n (%) 33 (36.3) 22 (24.2) 0.8 (0.3, 2.0)10 0.8 (0.3, 2.0)10
Absent right great toe position sense, n (%) 4 (4.4) 4 (4.4) 1.4 (0.4, 5.1)10 1.4 (0.4, 5.1)10
Absent right great toe vibration sense, n (%) 57 (62.6) 52 (62.6) 0.8 (0.4, 1.4)10 0.8 (0.4, 1.4)10
Timed up-and-go, s 10.4 6 2.6 10.7 6 3.2 20.12 (20.6, 0.4) 20.13 (20.7, 0.4)
1CMAP, compound muscle action potential; SAP, sensory action potential.
2ANCOVA models were adjusted for baseline neurologic function.
3Unless otherwise stated, all values are mean differences; 95% CIs in parentheses.
4ANCOVA models were adjusted for baseline neurologic function, age, and sex.
5Median; range in parentheses (all such values).
6Mean 6 SE (all such values).
7Missing data (n = 19 in vitamin B-12 and n = 15 in placebo).
8Missing data (n = 22 in vitamin B-12 and n = 22 in placebo).
9Small amounts of missing data (n , 10 in each arm).
10OR; 95% CI in parentheses.
TABLE 6
Effects of vitamin B-12 on cognitive and psychological function outcomes at 12 mo
Vitamin B-12 (n = 91) Placebo (n = 93) Unadjusted effect size1 Adjusted effect size2
California Verbal Learning Test
Total words correct in first 3 trials, n 23.9 6 0.73 24.6 6 0.7 21.4 (22.9, 0.1)4 21.4 (22.9, 0.1)
Words recalled at delayed recall, n 7.5 6 0.3 7.7 6 0.4 20.4 (21.0, 0.2) 20.4 (21.0, 0.2)
Symbol letter modality, n correct 39.6 6 1.1 40.1 6 1.2 21.3 (23.2, 0.6) 21.3 (23.2, 0.6)
Reaction time, s
Simple 0.3 6 0.01 0.3 6 0.01 0.01 (20.02, 0.04) 0.01 (20.02, 0.04)
Choice 0.7 6 0.01 0.7 6 0.02 20.003 (20.03, 0.02) 20.003 (20.03, 0.02)
Verbal fluency, n animals named 20.8 6 0.5 19.9 6 0.6 1.1 (20.1, 2.2) 1.1 (20.1, 2.2)
30-item General Health Questionnaire score5 2.4 6 0.5 2.7 6 0.5 20.1 (21.2, 1.0) 20.1 (21.3, 1.1)
1ANOVA models were adjusted for baseline cognitive function.
2ANOVA models were adjusted for baseline cognitive function, age, and sex.
3Mean 6 SE (all such values).
4Mean difference; 95% CI in parentheses (all such values).
5Missing data (n = 5 in vitamin B-12 and n = 11 in placebo).
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and disturbance for participants, and we had high participant
retention.
Study exclusion criteria resulted in the selection of relatively
healthy and highly functioning participants who may have been
less likely to benefit from vitamin B-12 supplementation. There
are no age-specific reference data for neurologic function in older
people (31), and norms for cognitive function (32, 33) are rarely
population specific, which make interpretation problematic. It
may be that neurologic and cognitive function was not impaired
in study participants at baseline. However, this trial was designed
to identify neurologic and cognitive benefits from vitamin B-12
supplementation in older people with moderate vitamin B-12
deficiency irrespective of baseline function. Because of the
healthy nature of trial participants, the results may not be fully
generalizable to all older people in the population. It is also
possible that the duration of treatment may have been too short,
and any effects of vitamin B-12 supplementation may only be-
come evident after several years of supplementation or follow-up
(34). No relevant trial with vitamin B-12 supplementation .2 y
has been conducted to our knowledge (34). The dose of vitamin
B-12 used in the study may have been insufficient. We selected
a safe dose that was within current guidelines, and the in-
tervention profoundly improved vitamin B-12 and holo-
transcobalamin status. Finally, the sample might have been too
small adequately to detect a small change. The study had ade-
quate power to detect a 28% change in the primary neurologic
outcome with the assumption of a test-retest correlation of 0.6.
Our test-retest correlation was 0.8, which suggested that we had
power to detect a smaller change than was originally planned.
Observational studies have reported direct associations of
vitamin B-12 status with nerve conduction (6), although this
result has not been a consistent finding (7, 9, 35). To our
knowledge, there has been no previous randomized controlled
trial that assessed the impact of vitamin B-12 supplementation on
neurologic function in older people. Previous trials of the effect of
vitamin B-12 supplementation on cognitive function have largely
shown no benefits of supplementation but have been of variable
quality, small size, and short duration (10, 34). Some evidence of
a benefit from multiple B-vitamin supplementation was recently
reported, especially in subgroups of individuals with worse
biochemical status when randomly assigned at baseline (36, 37).
Our trial contributes robust evidence on the effect of vitamin B-12
on cognitive function in later life, and our findings are consistent
with a recent meta-analysis that showed no effect of supple-
mentation with vitamin B-12 on cognitive aging (38).
In conclusion, the current study did not detect any benefits of
daily vitamin B-12 supplementation over 1 y on neurologic or
cognitive function in asymptomatic, nonanemic older people
with moderate vitamin B-12 deficiency. These results are directly
relevant to current clinical practice, which identifies low vitamin
B-12 status, especially in older people, as being a risk factor for
neurologic and cognitive impairments. Moreover, the results of the
current study cast doubt on the relevance of screening for moderate
vitamin B-12 deficiency in the absence of anemia and symptoms of
neurologic or cognitive impairment, suggesting the need for more-
stringent definitions of vitamin B-12 deficiency (30). Our findings
suggest that, with regard to peripheral motor and sensory nerve
conduction, central motor conduction, and cognitive function,
concerns over moderate vitamin B-12 deficiency in the absence of
anemia in asymptomatic, older adults may not be justified.
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